Romiplostim plus steroids for newly diagnosed ITP
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with primary ITP within the last 3 months.
- You have not received any ITP treatments before.
- Your platelet count is below 30,000 per microliter.
- You are in generally good health (able to carry out daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, orelabrutinib and romiplostim, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to or cannot tolerate standard treatments. The goal is to see if this combination can raise platelet levels and reduce bleeding risk.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
This trial tests a combination of two common medicines (atorvastatin and NAC) plus romiplostim to treat ITP when steroids have stopped working or stopped working. It may help raise your platelet counts.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.